摘要
Abstract
Objective the Evaluation of Edaravone spontaneous subarachnoid hemorrhage and safety. Methods By computer search, manual search and obtain information to pharmaceutical companies, a comprehensive collection of edaravonespontaneous subarachnoid hemorrhage randomized controlled trials, according to the Cochrane Collaboration systematic review evalua-ted. Results Finally the number of randomized controlled trials completed were 12, a total of 778 cases of patients. Meta-analysis showed that edaravone combined with conventional treatment could reduce adverse outcomes in patients with March occurred [ OR =0. 42, 95% CI (0. 28, 0. 62)], as compared with the control group, the difference was statistically significant;Edaravone combined with conventional treatment could reduce the symptoms of cerebral vasospasm [OR = 0. 38, 95% CI (0. 24, 0. 62)]and secondary cerebral infarction [OR = 0. 30, 95% CI (0. 15, 0. 59)].However, the systematic reviews of clinical trials have not describe the specific methods of randomization, allocation concealment unclear, blinding scheme unreported, so the possibility of bias in all stages of selection, implementation and measurement large, We should be cautious to choose the results of this systematic review . among them, five of the 12 trials reported edaravone-related adverse reactions, the most common abnormal liver function, the difference was not statistically significant. Conclusion Edaravone spontaneous subarachnoid hemorrhage can improve short-term and long-term prognosis of patients, with fewer adverse reactions. But lower quality of existing research, future studies should overcome the short-comings of existing studies, with particular attention to the correct method of random assignment, adequate allocation concealment, blinded outcome assessment and use of placebo controls.关键词
依达拉奉/蛛网膜下腔出血/Meta分析/系统评价Key words
edaravone/subarachnoid hemorrhage/meta analysis/system assessment分类
临床医学
